Senseonics (NYSE:SENS) said today that its Eversense continuous glucose monitoring system is available at clinics across the U.S.
The Germantown, Md.-based company also touted that it won coverage for its CGM with Horizon Blue Cross Blue Shield of New Jersey and Horizon Healthcare of New Jersey.
Get the full story at our sister site, Drug Delivery Business News.
The post Senseonics launches Eversense implantable glucose monitor appeared first on MassDevice.